ArticleBlood2007
Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.
Article in Blood, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Mechanistic approach on the protective role of rutin against ammonia-induced hepatic encephalopathy in Nile tilapia (Oreochromis niloticus) focusing on Cox-2/NF-κB pathway.Fish physiology and biochemistry · 2026Article
- PDGFR-α shRNA-polyplex for uveal melanoma treatment via EMT mediated vasculogenic mimicry interfering.Journal of nanobiotechnology · 2024Article
- Review
- Targeting of the COX-2/PGE2 axis enhances the antitumor activity of T7 peptideDrug delivery · 2021Article
- Role of Extracellular Matrix in Gastrointestinal Cancer-Associated Angiogenesis.International journal of molecular sciences · 2020Review
- A multi-targeted approach to suppress tumor-promoting inflammation.Seminars in cancer biology · 2015Review
- Construction of biological networks from unstructured information based on a semi-automated curation workflow.Database : the journal of biological databases and curation · 2015Article
- Type IV collagen α1-chain noncollagenous domain blocks MMP-2 activation both in-vitro and in-vivo.Scientific reports · 2014Article
- Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors.Journal of cancer science & therapy · 2013Article
- Extra cellular matrix derived metabolite regulates angiogenesis by FasL mediated apoptosis.PloS one · 2013Article
- L-arginine mediated renaturation enhances yield of human, α6 Type IV collagen non-collagenous domain from bacterial inclusion bodies.Protein and peptide letters · 2012Article
- Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation.Journal of oncology · 2012Article
- Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix.Pharmaceuticals (Basel, Switzerland) · 2011Article
- Maspin regulates endothelial cell adhesion and migration through an integrin signaling pathway.The Journal of biological chemistry · 2010Article
- Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF.The American journal of pathology · 2010Article
- Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells.Cancer research · 2010Article
- Validation of Different Systems for Tumstatin Expression and its in-vitro and iv-vivo Activities.Journal of cancer science & therapy · 2010Article
- Inhibitory effects of arresten on bFGF-induced proliferation, migration, and matrix metalloproteinase-2 activation in mouse retinal endothelial cells.Current eye research · 2010Article
- FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IV)NC1.Investigative ophthalmology & visual science · 2009Article
- The anti-tumor properties of two tumstatin peptide fragments in human gastric carcinoma.Acta pharmacologica Sinica · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
Abstract
Human alpha3 chain, a noncollagenous domain of type IV collagen [alpha3(IV)NC1], inhibits angiogenesis and tumor growth. These biologic functions are partly attributed to the binding of alpha3(IV)NC1 to alphaVbeta3 and alpha3beta1 integrins. alpha3(IV)NC1 binds alphaVbeta3 integrin, leading to translation inhibition by inhibiting focal adhesion kinase/phosphatidylinositol 3-kinase/Akt/mTOR/4E-BP1 pathways. In the present study, we evaluated the role of alpha3beta1 and alphaVbeta3 integrins in tube formation and regulation of cyclooxygenase-2 (COX-2) on alpha3(IV)NC1 stimulation. We found that although both integrins were required for the inhibition of tube formation by alpha3(IV)NC1 in endothelial cells, only alpha3beta1 integrin was sufficient to regulate COX-2 in hypoxic endothelial cells. We show that binding of alpha3(IV)NC1 to alpha3beta1 integrin leads to inhibition of COX-2-mediated pro-angiogenic factors, vascular endothelial growth factor, and basic fibroblast growth factor by regulating IkappaBalpha/NFkappaB axis, and is independent of alphaVbeta3 integrin. Furthermore, beta3 integrin-null endothelial cells, when treated with alpha3(IV)NC1, inhibited hypoxia-mediated COX-2 expression, whereas COX-2 inhibition was not observed in alpha3 integrin-null endothelial cells, indicating that regulation of COX-2 by alpha3(IV)NC1 is mediated by integrin alpha3beta1. Our in vitro and in vivo findings demonstrate that alpha3beta1 integrin is critical for alpha3(IV)NC1-mediated inhibition of COX-2-dependent angiogenic signaling and inhibition of tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.